NIH funding opportunities

Faculty of Medicine and Health Sciences: Research Development and Support **12 Oct 2015**

[Click on blue hyperlink for further information]

*The NIH funding opportunities listed below are only a **selection** of pre-screened, currently open health funding opportunities for which **South African institutions are eligible to apply**. For a comprehensive selection of NIH funding opportunities, please visit www.grants.nih.gov.*

*Please be advised that you **must contact the Research Grants Management Office (RGMO) at least 60 days before the submission date**, Mr Eugene Baugaard (eugeneb@sun.ac.za), or as soon as you commit to apply for an NIH grant and that the grant is submitted institutionally. **All final application documents MUST reach the RGMO seven (7) workdays before NIH application due date**.*

Important notices

- **Stay Mindful of Federal Law and NIH Policy on Select Agents Before you apply for NIAID funding, you should first know whether your proposed research includes a select agent and how to proceed if it does.**
- **US and Canada partner to invest $21 million for research hubs in developing countries Hubs will address environmental and occupational health issues.**
- **Apply for Grand Challenges Funding If you're working on ID-related topics, check out two Grand Challenges programs from the Bill and Melinda Gates Foundation.**
- **Know the Importance of Civil Rights Protections in NIH-Supported Activities To provide a nondiscriminatory research and research-related environment, grantee institutions, PIs, and others who administer NIH-funded activities must identify and eliminate any barriers to participation.**
- **Important Reminder: Abide by Biosketch Rules With numerous application deadlines coming up, we want to give you this important reminder: Be sure to use the new biosketch format announced in the December 5, 2014 *Guide* notice. If you haven't already, become familiar with how the new biosketch differs from the old. One of the changes is that you now have five pages (versus four pages previously). Don't exceed the five-page limit since doing so will result in an error during the eRA Commons validations process. That means your application won't move forward until you make corrections. For more information on the new biosketch format, go to NIH's Biosketches Frequently Asked Questions, including What application submission validations will eRA systems enforce for biosketches? and What does it mean to be compliant with the new biosketch policy?**
- **Notice of Correction for Foreign Institutions Eligibility for PAR-15-348 "Research on Informal and Formal Caregiving for Alzheimer's Disease (R01)" (NOT-AG-16-001)**
- **Notice of Correction for Foreign Institutions Eligibility for PAR-15-349 "Health Disparities and Alzheimer's Disease (R01)" (NOT-AG-16-002)**
- **Notice of Correction for Foreign Institutions Eligibility for PAR-15-350 "Emerging Directions for Addressing Health Disparities in Alzheimer's Disease (R03)" (NOT-AG-16-003)**
- **Notice of Correction for Foreign Institutions Eligibility for PAR-15-351 "Research on Informal and Formal Caregiving for Alzheimer's Disease (R21)" (NOT-AG-16-004)**
- **Notice of Correction for Foreign Institutions Eligibility for PAR-15-356 "Major Opportunities for Research in Epidemiology of Alzheimer's Disease and Cognitive Resilience (R01)" (NOT-AG-16-005)**
- **Notice of Correction for Foreign Institutions Eligibility for PAR-15-357 "Understanding Alzheimer's Disease in the Context of the Aging Brain (R01)" (NOT-AG-16-006)**
- **Notice of Correction for Foreign Institutions Eligibility for PAR-15-358 "Capturing Complexity in the Molecular and Cellular Mechanisms Involved in the Etiology of Alzheimer's Disease (R01)" (NOT-AG-16-007)**
- **Notice of Correction for Foreign Institutions Eligibility for PAR-15-359 "Novel Approaches to Diagnosing Alzheimer's Disease & Predicting Progression (R01)" (NOT-AG-16-008)**
- **Notice of NIA Participation in PAR-16-363 "Multi-Site Randomized Controlled Clinical Trial Research Center on Alcohol's Health Effects (U10)" (NOT-AG-16-009)**
- **Notice of Change in Application Due Date for RFA-DE-16-002 "Oral Immune Plasticity in Chronic HIV Infection Under Treatment and Oral Co-Infections (R01)" (NOT-DE-15-006)**
- **Notice of Participation of the National Institute of Environmental Health Sciences (NIEHS) in RFA-HD-16-037 "Using Omics to Define Human Placental Development and Function Across Pregnancy (R21)" (NOT-ES-16-001)**
- **Request for Information (RFI): Future Directions in Gynecologic Health and Disease Research (NOT-HD-15-030)**
- **Notice of Plans for NHGRI Implementation of NIH Genomic Data Sharing Policy (NOT-HG-15-038)**
- **Request for Information (RFI): Undiagnosed Diseases Research (NOT-RM-16-001)**
- **Request for Information (RFI): Input on Validation Assays for Affinity Reagents Generated by the NIH Common Fund Protein Capture Reagents Program (NOT-RM-16-002)**
- **Notice of National Biosafety Stewardship Month and Health and Safety Requirements for NIH Grantees**

(NOT-OD-15-163)

- **NIH/HHS Contingency Plans for the Grants Administration Process Given a Potential Lapse in Funding (NOT-OD-15-164)**
- **NIH Operates Under a Continuing Resolution (NOT-OD-16-002)**
- **Notice of Technical Assistance Webinar and Follow-Up Conference Call for the Adolescent Medicine Trials Network for HIV/AIDS Interventions (ATN) Research Program Grants (U19) and the (ATN) Coordinating Center (CC) (U24) (NOT-HD-15-029)**
- **Notice of Clarification to RFA-HL-17-006 "Sickle Cell Disease in Sub-Saharan Africa: Collaborative Consortium (U24) (NOT-HL-15-272)**
- **Notice of Availability of Frequently Asked Questions and Webinar for RFA-HL-17-006 "Sickle Cell Disease in Sub-Saharan Africa: Collaborative Consortium (U24) (NOT-HL-15-274)**
- **Notice of Availability of Frequently Asked Questions for RFA-HL-17-007 "Sickle Cell Disease in Sub-Saharan Africa: Data Coordinating Center (U24)" (NOT-HL-15-275)**

1. Title: Limited Competition: Understanding How Epigenetics and Infections Impact Autoimmunity and Diabetes in The Environmental Determinants of Diabetes In The Young Study (TEDDY)

Letter of Intent due date: February 3, 2016 **Hyperlink:** (RFA-DK-15-506) **Type:** UC4

Application Due Date. March 3, 2016. Apply by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. ***Applicants should be aware that on-time submission means that an application is submitted error free to of both Grants.gov and eRA Commons.*** Internal Submission will be 2 days before the application due date above.

Purpose: This FOA invites a High Impact Research and Research Infrastructure Cooperative Agreement application (UC4) from the Program Director/Principal Investigator (PD/PI) of the Data Coordinating Center (DCC) that has been involved in study design and coordination, and data and biosample acquisition and management, since the inception of The Environmental Determinants of Diabetes in the Young (TEDDY) consortium, an ongoing epidemiological study. This FOA provides support for the TEDDY DCC to continue to follow TEDDY children, allowing collaborators to conduct further studies in the measurement and analysis of epigenetic marks and infectious exposures using samples from TEDDY subjects.

Budget: Application budgets are limited to $22,000,000 in direct costs for the entire project period. Funds for the entire duration of the project will be awarded in the first year. The maximum project period is 4 years 9 months.

2. Title: Characterization of Mycobacterial Induced Immunity in HIV-infected and Uninfected Individuals

Letter of Intent due date: N/A **Hyperlink:** (PAR-15-360) **Type:** R21

Application Due Date: January 11, 2016; January 11, 2017; and January 11, 2018. Apply by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. ***Applicants should be aware that on-time submission means that an application is submitted error free*** (of both Grants.gov and eRA Commons errors) by 8:00 PM Eastern Time on the application due date. Internal Submission will be 2 days before the application due date above.

Purpose: The purpose of this FOA is to support hypothesis-generating research on innate and adaptive immune responses induced by mycobacterial infection, Bacillus Calmette-Guérin vaccine (BCG), or other Mycobacterium tuberculosis (Mtb) vaccinations. Studies that include evaluation of immune responses by anatomical location in HIV-infected or uninfected individuals are of particular interest. A secondary objective of this FOA is development of new assays and technologies enabling comparison of mycobacterial-specific mucosal and systemic immunological pathways in HIV-infected or uninfected individuals that can be used to monitor immune responses in preclinical studies and vaccine trials to advance Mtb vaccine development.

Budget: Application budgets are limited to $275,000 direct costs over two years, with no more than $200,000 direct costs being requested in a single year. The total Project period may not exceed 2 years.

3. Title: Cancer Detection, Diagnosis, and Treatment Technologies for Global Health

Letter of Intent due date: January 9, 2016. One month before the due date **Hyperlink:** (RFA-CA-15-024) **Type:** UG3/UH3

Application Due Date: February 9, 2016. Apply by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. ***Applicants should be aware that on-time submission means that an application is submitted error free*** (of both Grants.gov and eRA Commons errors) by 8:00 PM Eastern Time on the application due date. Internal Submission will be 2 days before the application due date above.

Purpose: This FOA supports the development of cancer-relevant technologies suitable for use in ***low- and middle-income countries (LMICs)***. Specifically, the FOA solicits applications for projects to adapt, apply, and validate existing or emerging technologies into a new generation of user-friendly, low-cost technologies for imaging, detecting, diagnosing, preventing, and/or treating cancers in humans living in LMICs. UG3 applicants should have a working assay or device prototype (not necessarily already capable of cancer applications). The initial UG3 exploratory phase will be a feasibility study to demonstrate technical functionality and clinical potential for use of the device or assay in LMIC settings by meeting specific performance milestones. UG3 projects that have met their milestones will be administratively considered by NCI and prioritized for transition to the UH3 validation phase. UH3 awards will support improvements and validations of the technologies in the LMIC settings. Projects proposed in response to this FOA will require multidisciplinary efforts to succeed; therefore, all applicant teams must include expertise in engineering/assay/treatment development, oncology, global healthcare delivery, and business development. Investigators responding to this FOA must address both the UG3 and UH3 phases.

Budget: Applicants may request up to $325,000 direct costs for the UG3 phase per year and up to $650,000 direct costs for the UH3 phase per year. The proposed project period for the initial development phase (UG3) must not exceed 2 years (but may be shorter).The proposed project period for the second validation phase (UH3) must not exceed 3 years.

4. Title: Research Using Biosamples and Subjects from Type 1 Diabetes Clinical Studies Complications

Letter of Intent due date: February 3, 2016 i.e. one month before the due date **Hyperlink:** (RFA-DK-15-019) **Type:** DP3

Application Due Date: March 3, 2016. Apply by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. ***Applicants should be aware that on-time submission means that an application is submitted error free*** (of both Grants.gov and eRA Commons errors) by 8:00 PM Eastern Time on the application due date. Internal Submission will be 2 days before the application due date above.

Purpose: This FOA invites applications for studies on the complications of type 1 diabetes using subjects and/or samples from clinical studies on type 1 diabetes.

Budget: The maximum direct costs are $1 million for the entire project period. Facilities and Administrative (F&A) costs to be determined at the time of award. F&A costs requested by consortium participants are not included in the direct cost limitation. The scope of the proposed project should determine the project period. The maximum project period is 3 years.

5. Title: Limited Competition: Knockout Mouse Phenotyping Project Database

Letter of Intent due date: N/A **Hyperlink:** (RFA-RM-15-016) **Type:** UM1

Application Due Date: December 9, 2015. Apply by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. ***Applicants should be aware that on-time submission means that an application is submitted error free*** (of both Grants.gov and eRA Commons errors) by 8:00 PM Eastern Time on the application due date. Internal Submission will be 2 days before the application due date above.

Purpose: This initiative is funded through the NIH Common Fund, which supports cross-cutting programs that are expected to have exceptionally high impact. All Common Fund initiatives invite investigators to develop bold, innovative, and often risky approaches to address problems that may seem intractable or to seize new opportunities that offer the potential for rapid progress. The purpose of the Knockout Mouse Phenotyping Project (KOMP2) is to produce a comprehensive resource of null-mutant mice, and associated phenotype data, for the purpose of elucidating functional information for each protein-coding gene in the mammalian genome. The goal of this FOA is to provide informatics support to NIH funded projects that are performing high-throughput broad based phenotyping of mouse knock-out (KO) lines (see RFA-RM-15-017) and to coordinate with international efforts so as to integrate all data into a common database under the auspices of the International Mouse Phenotyping Consortium (IMPC). The Data Coordination Center and Database (DCCDB) will perform the curation, analysis, visualization, and dissemination of the phenotype data from the knockout lines. Curation will require integration with other data sources. Analysis will require further development and validation of statistical methods. Visualization and queries will require innovative tools to disseminate the data in a real-time environment. The ultimate goals of these efforts are to enhance the ability of the biomedical research community to identify new disease models, to better understand phenotypic patterns, and to gain a more comprehensive understanding of the underlying function of each gene.

Budget: Application budgets are not limited but need to reflect the actual needs of the proposed project. The total project period may not exceed five years.

6. Title: Collaborative Activities to Promote Metabolomics Research (Admin Supp)

Letter of Intent due date: One month before the due date **Hyperlink:** (PA-16-005) **Type:** Admin Sup

Application Due Date: Apply by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. ***Applicants should be aware that on-time submission means that an application is submitted error free*** (of both Grants.gov and eRA Commons errors) by 8:00 PM Eastern Time on the application due date. Internal Submission will be 2 days before the application due date above.

Purpose: This Administrative Supplement funding opportunity is part of the Common Fund Metabolomics Program created to increase and improve the nation's ability to undertake metabolomics analyses in translational and clinical research. Metabolomics has great potential to advance our understanding of human diseases, but requires specialized expertise in metabolomics study design, technology, and data analysis and interpretation. This FOA supports supplemental funds to current NIH-funded research projects for new interactive collaborations between basic or clinical researchers and metabolomics experts to add a metabolomics approach to the existing Research Strategy for the project. In addition to enhancing the parent grant by adding metabolomics analyses, collaborative projects must include activities to increase the expertise of the biomedical research group in key aspects of metabolomics study design, analysis, and data interpretation. All applicants are strongly encouraged to discuss potential requests with the awarding IC and with the Common Fund Metabolomics Scientific/Research contact listed below.

Budget: Application budgets are limited to no more than $100,000 direct costs, exclusive of consortium/contractual Facilities and Administrative (F&A) costs, and must reflect the actual needs of the proposed project. The funding mechanism being used to support this program, administrative supplements, can be used to cover cost increases that are associated with achieving certain new research objectives, as long as the research objectives are within the original scope of the peer reviewed and approved project. Any cost increases need to result from making modifications to the project that would increase or preserve the overall impact of the project consistent with its originally approved objectives and purposes. The project and budget periods must be within the currently approved project period for the existing parent award. Parent awards must be funded through June 30, 2017, exclusive of any no cost extension. Supplemental funding is limited to a maximum of 12 months of funding and must commence in fiscal year 2016.

7. Title: Phase III Clinical Trials for the Spectrum of Alzheimer's Disease and Age-related Cognitive Decline

Letter of Intent due date: November 11, 2105. One month before the due date **Hyperlink:** (PAR-16-364) **Type:** RO1

Application Due Date: December 11, 2015 (New, Revision, and Resubmission applications) followed by Standard dates. Apply by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. ***Applicants should be aware that on-time submission means that an application is submitted error free*** (of both Grants.gov and eRA Commons errors) by 8:00 PM Eastern Time on the application due date. Internal Submission will be 2 days before the application due date above.

Purpose: This FOA encourages R01 grant applications that propose to develop and implement Phase III clinical trials of promising pharmacological and non-pharmacological interventions in individuals with age-related cognitive decline and across the Alzheimer's disease (AD) spectrum from pre-symptomatic to more severe stages of disease.

Budget: NIH intends to fund an estimate of 8 -10 awards, corresponding to a total of $25 million for fiscal year 2016. Future year amounts will depend on annual appropriations. Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years

8. Title: Pilot Clinical Trials for the Spectrum of Alzheimers Disease and Age-related Cognitive Decline

Letter of Intent due date: N/A **Hyperlink:** (PAR-16-365) **Type:** RO1

Application Due Date: December 16, 2015 (New, Resubmission, and Revision applications) followed by Standard dates Apply by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. ***Applicants should be aware that on-time submission means that an application is submitted error free*** (of both Grants.gov and eRA Commons errors) by 8:00 PM Eastern Time on the application due date. Internal Submission will be 2 days before the application due date above.

Purpose: This FOA invites applications that propose to develop and implement Phase I or II clinical trials of promising pharmacological and non-pharmacological interventions in individuals with age-related cognitive decline and in individuals with Alzheimer's disease (AD) across the spectrum from pre-symptomatic to more severe stages of disease, as well as to stimulate studies to enhance trial design and methods.

Budget: NIH intends to fund an estimate of 10 - 15 awards, corresponding to a total of $10 million for fiscal year 2016. Future year amounts will depend on annual appropriations. Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

Brief definitions of some NIH grant mechanisms: **comprehensive list of extramural grant and cooperative agreement activity codes**

DP3 – Institutional Training and Director Program Projects -Type 1 Diabetes Targeted Research Award: To support research tackling major challenges in type 1 diabetes and promoting new approaches to these challenges by scientific teams.

P20 – Research Program Projects and Centers -Exploratory Grant: To support planning for new programs, expansion or modification of existing resources, and feasibility studies to explore various approaches to the development of interdisciplinary programs that offer potential solutions to problems of special significance to the mission of the NIH. These exploratory studies may lead to specialized or comprehensive centers.

U01 – NIH Research Project Cooperative Agreement: supports discrete, specified, circumscribed projects to be performed by investigator(s) in an area representing their specific interests and competencies; many types of cooperative agreements, e.g. Clinical Trials Centers; generally no budget upper limit but may be specified.

UC4 – NIH Research Project Cooperative Agreement: To support multi-year funded cooperative agreement research with high impact ideas that may lay the foundation for new fields of investigation; accelerate breakthroughs; stimulate early and applied research on cutting-edge technologies; foster new approaches to improve the interactions among multi- and interdisciplinary research teams; or, advance the research enterprise in a way that could stimulate future growth and investments and advance public health and health care delivery. This activity code could support either a specific research question or propose the creation of a unique infrastructure/resource designed to accelerate scientific progress in the future.

U24 – Resource-Related Research Projects – Cooperative Agreements: To support research projects contributing to improvement of the capability of resources to serve biomedical research.

R01 – NIH Research Project Grant Program: most common NIH program; to support a discrete, specified, circumscribed research project; generally 3-5 years; budget may be specified, but generally <$500,000 p.a. (direct costs).

R03 – NIH Small Grant Program: limited funding for short period to support e.g. pilot / feasibility study, collection of preliminary data, secondary analysis of existing data, small-contained research projects, development of new research technology, etc.; normally for "new investigators"; not renewable; up to 2 years; budget generally <$50,000 (direct costs).

R21 – NIH Exploratory/Developmental Research Grant: encourages new, exploratory and developmental research projects (could be used for pilot or feasibility studies); up to 2 years; budget total generally <$275,000 (direct costs).

R21/R33 - Phased Innovation: The R33 award is to provide a second phase for the support for innovative exploratory and development research activities initiated under the R21 mechanism. Although only R21 awardees are generally eligible to apply for R33 support, specific program initiatives may establish eligibility criteria under which applications could be accepted from applicants demonstrating progress equivalent to that expected under R33.

Complete Glossary and acronym list of NIH Terms

Research Development and Support Division (RDSD), Faculty of Medicine and Health Sciences, Stellenbosch University
5th Floor, Teaching Block, Tygerberg Campus. • Enquiries: ***Dr Christa Coetsee*** • Tel: 9838 • Email: cdevries@sun.ac.za